#1 Clinical Trials Search in Europe

Etranacogene Dezaparvovec

Etranacogene Dezaparvovec, also known as CSL222 or Hemgenix, is an innovative gene therapy being studied in clinical trials for the treatment of hemophilia B. This article explores the ongoing research into this groundbreaking therapy, which aims to provide long-term relief for patients with severe or moderately severe hemophilia B by addressing the underlying genetic cause of the condition.

Table of Contents

What is Etranacogene Dezaparvovec?

Etranacogene dezaparvovec, also known by its brand name Hemgenix, is a groundbreaking gene therapy developed for the treatment of hemophilia B, a rare genetic bleeding disorder[1]. This innovative therapy is designed to address the underlying cause of hemophilia B by providing a functional copy of the factor IX gene, which is defective in people with this condition.

How Does It Work?

Etranacogene dezaparvovec is a gene therapy that uses a modified virus called adeno-associated virus serotype 5 (AAV5) as a vector to deliver a functional copy of the factor IX gene to liver cells[2]. The therapy contains:

  • A codon-optimized cDNA of the human coagulation Factor IX variant R338L (FIX-Padua)
  • A liver-specific promoter (LP1) to ensure the gene is expressed in liver cells

Once administered, this gene therapy enables the patient’s liver to produce functional factor IX protein, potentially reducing or eliminating the need for regular factor IX replacement therapy.

Medical Conditions Treated

Etranacogene dezaparvovec is specifically designed to treat:

  • Hemophilia B (Factor IX deficiency): A rare genetic disorder characterized by impaired blood clotting due to a deficiency in coagulation factor IX[1]

The therapy is intended for adult patients with:

  • Severe hemophilia B (factor IX activity ≤2% of normal)
  • Moderately severe hemophilia B (factor IX activity ≤2% of normal)

Administration and Dosage

Etranacogene dezaparvovec is administered as a one-time treatment through intravenous (IV) infusion[1]. The typical dosage is:

  • 2 milliliters per kilogram of body weight

This single-dose administration is designed to provide long-term therapeutic benefits, potentially eliminating the need for regular factor IX replacement therapy.

Efficacy and Benefits

Clinical trials have shown promising results for etranacogene dezaparvovec, including[2]:

  • Increased endogenous factor IX activity
  • Reduced annualized bleeding rate (ABR)
  • Decreased need for factor IX replacement therapy
  • Improved quality of life for patients

Specific benefits observed in clinical trials include:

  • Sustained factor IX activity levels at 6, 12, and 18 months post-treatment
  • Reduction in spontaneous and joint bleeding events
  • A high proportion of patients remaining free of continuous routine prophylaxis
  • Improved scores on quality of life questionnaires such as EQ-5D-5L and Hemophilia Quality of Life Questionnaire (Hem-A-QoL)

Safety and Side Effects

While etranacogene dezaparvovec has shown a favorable safety profile, ongoing studies are monitoring for potential side effects and long-term safety[3]. Some areas of focus include:

  • Adverse events related to the therapy
  • Changes in liver function (monitored through ALT/AST levels)
  • Development of antibodies against factor IX or the AAV5 vector
  • Liver health (assessed through ultrasound and alpha-fetoprotein levels)

Patients receiving the therapy are closely monitored for these and other potential side effects.

Ongoing Research

Several clinical trials are currently underway to further evaluate the long-term safety and efficacy of etranacogene dezaparvovec[1][2][3]. These studies aim to:

  • Assess the therapy’s effectiveness over extended periods (up to 15 years post-treatment)
  • Monitor long-term safety profiles
  • Evaluate the durability of factor IX expression
  • Investigate the therapy’s impact on patients’ quality of life and joint health

These ongoing studies will provide valuable insights into the long-term benefits and potential risks of etranacogene dezaparvovec, helping to establish its role in the treatment of hemophilia B.

Aspect Details
Drug Name Etranacogene Dezaparvovec (CSL222, Hemgenix)
Type of Therapy Gene therapy for Hemophilia B
Administration Single intravenous infusion
Target Population Adult males with severe or moderately severe Hemophilia B
Primary Objectives Assess long-term safety and efficacy (5-15 years post-treatment)
Key Efficacy Measures Annualized bleeding rate, factor IX activity, factor IX replacement therapy use
Safety Monitoring Adverse events, liver function, antibody formation, vector shedding
Quality of Life Assessments EQ-5D-5L, Hemophilia Quality of Life Questionnaire, physical activity measures
Trial Phases Phase I/IIb extension and Phase III studies
Unique Features Potential for long-term factor IX production, reduced need for prophylaxis

FAQ

  • What is Etranacogene Dezaparvovec? Etranacogene Dezaparvovec is a gene therapy designed to treat hemophilia B. It uses a modified virus (AAV5) to deliver a functional copy of the factor IX gene to liver cells, potentially allowing patients to produce their own clotting factor IX.
  • How is Etranacogene Dezaparvovec administered? Etranacogene Dezaparvovec is administered as a single intravenous infusion. The typical dose is 2 milliliters per kilogram of body weight.
  • What are the main goals of the clinical trials? The main goals of the clinical trials are to assess the long-term safety and efficacy of Etranacogene Dezaparvovec in adults with severe or moderately severe hemophilia B, including its ability to reduce bleeding episodes and the need for factor IX replacement therapy.
  • How long do the clinical trials follow patients? The clinical trials follow patients for extended periods, ranging from 5 to 15 years after treatment, to evaluate the long-term effects and durability of the gene therapy.
  • What are some of the key outcomes being measured in these trials? Key outcomes include annualized bleeding rate, factor IX activity levels, use of factor IX replacement therapy, quality of life measures, and safety assessments such as monitoring for adverse events and liver function tests.

Ongoing Clinical Trials on Etranacogene Dezaparvovec

  • Study of Etranacogene Dezaparvovec (CSL222) in Adolescent Males with Severe or Moderately Severe Hemophilia B

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium France Spain

  • Study on the Safety and Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Adults with Severe or Moderately Severe Hemophilia B and AAV5 Antibodies

    Recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria Poland

  • Title: Study of gene therapy Etranacogene Dezaparvovec (Hemgenix) in adult patients with moderate to severe Hemophilia B

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Denmark Germany Ireland The Netherlands Sweden

  • Long-term Safety Study of Etranacogene Dezaparvovec in Adult Men with Hemophilia B

    Not recruiting

    4 1 1 1
    Investigated drugs:
    Belgium Denmark Germany Ireland The Netherlands Sweden

  • Study on Long-Term Safety and Efficacy of Etranacogene Dezaparvovec for Adults with Severe or Moderately Severe Hemophilia B

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Germany The Netherlands

Glossary

  • Hemophilia B: A genetic bleeding disorder caused by a deficiency in blood clotting factor IX, which can lead to prolonged bleeding and spontaneous internal bleeding.
  • Factor IX: A protein in the blood that plays a crucial role in the clotting process. People with hemophilia B have low levels or dysfunctional factor IX.
  • Gene therapy: A technique that uses genes to treat or prevent disease. In this case, it involves introducing a functional copy of the factor IX gene into the patient's cells.
  • AAV5: Adeno-associated virus serotype 5, a type of virus modified for use in gene therapy to deliver genetic material to cells.
  • Annualized Bleeding Rate (ABR): A measure of how often a person with hemophilia experiences bleeding episodes over a year, used to assess the effectiveness of treatments.
  • Prophylaxis: Preventive treatment, typically involving regular infusions of clotting factor to prevent bleeding episodes in people with hemophilia.
  • Endogenous: Originating or produced within the body. In this context, it refers to the body's own production of factor IX after gene therapy.
  • Target joint: A joint that has experienced repeated bleeding episodes, often leading to chronic damage in people with hemophilia.
  • Factor IX inhibitors: Antibodies that the immune system develops against factor IX, which can make treatment less effective.
  • Quality of Life (QoL): A measure of an individual's overall well-being and ability to function in daily life, often assessed using standardized questionnaires in clinical trials.

References

  1. http://clinicaltrials.eu/trial/long-term-safety-study-of-etranacogene-dezaparvovec-in-adult-men-with-hemophilia-b/
  2. http://clinicaltrials.eu/trial/study-on-gene-therapy-etranacogene-dezaparvovec-for-adults-with-severe-or-moderately-severe-hemophilia-b/
  3. http://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-etranacogene-dezaparvovec-for-adults-with-severe-or-moderately-severe-hemophilia-b/